Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


HR+/HER2- Breast Cancer Market Set To Triple

Executive Summary

The HR-positive/HER2-negative breast cancer market is set to more than triple in value by 2022, according to a new forecast by Datamonitor Healthcare. The growth will be driven by a marketed product as well as the approval of several late-phase pipeline candidates. Generic and biosimilar drugs are expected to offset these sales from the beginning of 2023.

You may also be interested in...

Novartis CDK4/6 Profile Boosted But Challenge To Pfizer Rival Uncertain

Novartis' Phase III MONALEESA-2 trial shows that ribociclib plus letrozole has strong efficacy and an acceptable tolerability profile for first-line advanced HR+/HER2- breast cancer patients, but analysts say the results do not surpass those of Pfizer's first-to-market Ibrance plus letrozole in a similar setting.

EU Approval Recommendation Secures Ibrance Domination

The EMA’s CHMP has recommended Ibrance for HR+/HER2- breast cancer and Pfizer may be able to establish a dominant position in the EU even quicker than it did in the US.

Novartis Ups Pace On Ibrance Challenger As Ribociclib Trial Stopped Early

Novartis's Phase III MONALEESA-2 trial of its CDK4/6 inhibitor ribociclib has been stopped early on positive interim data. The study was conducted in first-line metastatic, hormone-positive breast cancer patients, a market estimated to be worth $6bn in the US alone.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts